Program
umeclidinium bromide
Also written as “Budesonide, Formoterol Fumarate, and Umeclidinium Bromide”, “Umeclidinium bromide 62.5mcg” and “Umeclidinium bromide 125mcg”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by 2 companies.
Drug pageUmeclidinium bromide: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 61 open or running | phase 4since Apr 15, 2024 | Jan 17, 2013 | none ahead |
| Chenpon Pharmaceutical | 10 open or running | phase 2since Aug 31, 2026 | Aug 31, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chenpon Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 31, 2026First study: phase 2 study in AsthmaFirst studyNCT07807007 · 150 enrolled · China
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist”ChEMBL 37, by rule
Other programs on CHRM3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| trospiumrule | Bristol-Myers Squibb | phase 4 | 21 |
| trospium chloriderule | Bristol-Myers Squibb | phase 4 | 15 |
| Atropinerule | Laboratorios Sophia S.A de C.V. | phase 3 | 17 |
| TQC3927 | Sino Biopharmaceutical | phase 2 | 3 |
| TQC3302 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
The one study Chenpon Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07807007Asthma · China | 2 | Completed | Aug 3, 2026 | 150 |
How it is read
Names in the registry
- “Budesonide, Formoterol Fumarate, and Umeclidinium Bromide”, 2 entries
- “Umeclidinium bromide 62.5mcg”, 2 entries
- “Umeclidinium bromide 125mcg”, 2 entries
- “Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate”, 1 entry
- “Umeclidinium bromide”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 5 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.